| 7th Jun 2021 7:00 am |
RNS |
Calquence head-to-head results versus ibrutinib |
| 4th Jun 2021 7:05 am |
RNS |
Lynparza reduced recurrence risk in breast cancer |
| 4th Jun 2021 7:00 am |
RNS |
AstraZeneca appoints new Chief Financial Officer |
| 2nd Jun 2021 7:00 am |
RNS |
Publication of Final Terms |
| 1st Jun 2021 3:01 pm |
RNS |
Block listing Interim Review |
| 1st Jun 2021 3:00 pm |
RNS |
Total Voting Rights |
| 28th May 2021 7:00 am |
RNS |
Tagrisso approved in EU in early lung cancer |
| 27th May 2021 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 27th May 2021 4:36 pm |
RNS |
Price Monitoring Extension |
| 27th May 2021 7:00 am |
RNS |
AstraZeneca prices a EUR800m bond offering |
| 26th May 2021 9:24 am |
RNS |
Stabilisation Notice |
| 26th May 2021 7:00 am |
RNS |
AstraZeneca prices a $7bn bond offering |
| 25th May 2021 7:00 am |
RNS |
EMTN programme update - publication of Prospectus |
| 21st May 2021 7:00 am |
RNS |
Vaxzevria COVID-19 vaccine approved in Japan |
| 18th May 2021 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th May 2021 2:00 pm |
RNS |
Result of AGM |
| 11th May 2021 1:55 pm |
RNS |
Shareholders vote in favour of Alexion acquisition |
| 7th May 2021 7:00 am |
RNS |
Imfinzi + tremelimumab showed survival in POSEIDON |
| 5th May 2021 6:30 pm |
RNS |
Holding(s) in Company |
| 4th May 2021 3:00 pm |
RNS |
Total Voting Rights |
| 4th May 2021 7:00 am |
RNS |
Farxiga approved in the US for CKD |
| 30th Apr 2021 7:00 am |
RNS |
AZN: First quarter 2021 results |
| 26th Apr 2021 7:10 am |
RNS |
Selumetinib recommended for EU approval in NF1 |
| 26th Apr 2021 7:05 am |
RNS |
Tagrisso adjuvant receives positive CHMP opinion |
| 26th Apr 2021 7:00 am |
RNS |
Nirsevimab Phase III trial met primary endpoint |
| 16th Apr 2021 12:00 pm |
RNS |
US clearance of proposed acquisition of Alexion |
| 14th Apr 2021 7:00 am |
RNS |
Tagrisso approved in China in early lung cancer |
| 12th Apr 2021 1:00 pm |
RNS |
Circular and notice of general meeting |
| 12th Apr 2021 7:00 am |
RNS |
Update on Farxiga COVID-19 DARE-19 Phase III trial |
| 1st Apr 2021 3:00 pm |
RNS |
Total Voting Rights |
| 30th Mar 2021 12:15 pm |
RNS |
Notice of AGM |
| 25th Mar 2021 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 25th Mar 2021 7:00 am |
RNS |
AZD1222 US Ph3 primary analysis confirms efficacy |
| 22nd Mar 2021 7:00 am |
RNS |
AstraZeneca US vaccine trial met primary endpoint |
| 16th Mar 2021 7:05 am |
RNS |
Divestment of Viela shareholding completed |
| 16th Mar 2021 7:00 am |
RNS |
US supply agreement for additional AZD7442 doses |
| 9th Mar 2021 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 4th Mar 2021 3:00 pm |
RNS |
Designation of EU home member state |
| 3rd Mar 2021 7:00 am |
RNS |
US court decision favours Symbicort patents |
| 2nd Mar 2021 7:00 am |
RNS |
Further update on roxadustat US regulatory review |
